Non-insulin type 2 diabetes Drugs Flashcards
Sulfonylureas
(glipizide, glyburide) stimulate pancreas to secrete more insulin & make tissues more responsive to insulin. Effective only when pancreas is capable of producing some insulin. (cannot be used in type 1 diabetes)
Meglitinides
(repaglinide, nateglinide) stimulate pancreas to secrete more insulin, repaglinide lowers BS by closing K+ channels of pancreatic beta cells. Shorter acting/should be taken with meals.
Thiazolidinediones
(glitazones- piolitazone, rosiglitazone) decrease insulin resistance at the tissue level and may also decrease glucose production.
Alpha-Glucosidase Inhibitors
(acarbose, miglitol) delay absorption of carbohydrates in small intestine, which decreases the expected rise in post prandial glucose after a meal
DPP-4 Inhibitors
(gliptins- sitagliptin, saxagliptin) enhance the actions of I cretin hormones, stimulating the release of insulin & suppressing the release of glucagon after eating, keeping blood glucose from elevating after meals.
Incretin Mimetics
(exenatide) non-injectable drugs, mimic effect of endogenous incretin. Gastric emptying is slowed, stimulating the glucose-dependent release of insulin, inhibiting the release of glucagon, and suppressing appetite.
Biguanides
(metformin) increases insulin sensitivity without causing hypoglycemia. Helpful with patients who are obese or who have hyperlipedemia because it also helps decrease weight, BP, and plasma lipids. (used in treatment of type 2 diabetes) slows production of glucose in liver/ decreased hepatic production of triglycerides and cholesterol
Glyburide (sulfonylurea)
Route: PO Onset of action: 0.25—1 hour Peak: 1-2 hours Duration: 12-24 hours Half-life: 5-6 hours Well absorbed in GI tract. Protein binding 99%. Metabolized in liver. Primarily excreted in urine. Not removed by hemodialysis.
Repaglinide (meglitinide)
Route: PO Onset of action: almost immediate Peak: 1 hour Duration: 4 hours Half-life: 1 hour Metabolized in liver and excreted in feces. Blood levels of insulin rise and fall in parallel with levels of repaglinide.
Piolitazone (thiazloidinedione)
Route: PO Onset of action: almost immediate Peak: 2 hours Duration: unknown Half-life: 16-24 hours Food slows absorption. Metabolized in liver, and excreted in urine
Acarbose (alpha - glucosidaze Inhibitor)
Route: PO
Onset of action: almost immediate
Very little drug is absorbed, systemic effects minimal, acts locally in intestine to slow absorption of carbs and is eliminated in feces
Sitagliptin (DPP-4 inhibitor)
Route: PO Onset of action: almost immediate Peak: 1-4 hours Duration: unknown Half-life: 12 hours Most of drug is excreted unchanged in urine.
Exenatide (incretin mimetic)
Route: SubQ Peak: 2.1 hours Duration: unknown Half-life: 2.4 hours Excreted unchanged in urine. Patients w/ mild to moderate renal impairment: clearance reduced only slightly. Should not be used in patients with end-stage renal disease; clearance is reduced significantly.
Diabetes mellitus
Complex disorder of carbohydrate, fat, & protein metabolism resulting from lack of insulin secretion by beta cells of the pancreas or from defects of insulin receptors.
Diabetic Ketoacidosis (DKA)
Severe metabolic complication of uncontrolled diabetes, if untreated can result in coma/death